Background and Aims Inflammation is increased in subjects with type 2 diabetes mellitus (T2DM) at risk of developing atherosclerosis. High density lipoproteins (HDL) transport cholesterol from cells and tissues back to the liver providing protection against the development of cardiovascular disease (CVD), which may be reduced by the release of serum amyloid A (SAA). Methods In a case-control study of young females, blood samples were compared between 84 subjects, T2DM (n=42) versus non-T2DM (n=42). HDL2 and HDL3 subfractions were isolated by rapid ultracentrifugation, and SAA and apolipoprotein AI (apoAI) concentrations, paraoxonase 1 (PON-1), cholesteryl ester transfer protein (CETP) and lecithin-cholesterol acyltransferase (LCAT) activities were measured in the serum and/or subfractions. Results SAA concentrations in serum, HDL2 and HDL3 were higher in individuals with T2DM compared to controls: serum [29573 μg/L (17211, 67664) versus 14911 μg/L (7037, 36008); p=0.002], HDL2 [956.5 μg/L (553.0, 2239.8) versus 386.7 μg/L (188.3, 722.1); p<0.001], and HDL3, [13083 μg/L (7802, 28615) versus 5809 μg/L (3147, 13314); p<0.001]. Serum PON-1 activity was significantly lower in participants with T2DM compared to controls [38245 U/L (7025) versus 41109 U/L (5690); p=0.043]. CETP activity was significantly higher in individuals with T2DM versus controls in HDL2 [232.6 μmoles (14.1) versus 217.1 μmoles (25.1); p=0.001] and HDL3 [279.5 μmoles (17.7) versus 245.2 μmoles (41.2); p<0.001]. Conclusions These results suggest individuals with T2DM have increased SAA-related inflammation and biochemical features of pro-atherogenic HDL. Consequently, SAA may prove a useful biomarker in subjects with T2DM in terms of predicting increased risk of CVD.
|Publication status||Published - 09 Jun 2017|
|Event||American Diabetes Associations 77th Scientific Conference - San Diego, United States|
Duration: 09 Jun 2017 → 13 Jun 2017
|Conference||American Diabetes Associations 77th Scientific Conference|
|Period||09/06/2017 → 13/06/2017|